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TherapyThe contribution of B cells and their products to the pathogenesis of MS has long been debated. The presence
of B cells, plasma cells and excess immunoglobulins in MS lesions and in the cerebrospinal ﬂuid of MS
patients implicate the humoral immune system in the disease. Correlations of higher levels of CSF B cells and
immunoglobulins found in some studies with a more aggressive clinical course of MS have bolstered the
notion that the humoral immune system is involved in MS pathogenesis. However, until the advent of
rituximab, a monoclonal antibody therapy that speciﬁcally lyses B cells, conﬁrmation of the key role of B cells
and their products in MS had been lacking. Development of this therapeutic monoclonal antibody to CD20, a
cell surface molecule conﬁned to B cells, allowed determination of the effects of B cell depletion. Perhaps
somewhat unexpectedly, depletion of circulating B cells led to rapid and profound reduction in gadolinium
enhancing lesions on brain MRI in three separate studies in relapsing MS subjects. When examined,
depletion of B cells in the blood was accompanied by depletion of B cells in CSF. Notably, reduction of
enhancing brain lesions was not accompanied by reduction in CSF immunoglobulins. Whether the critical
role of B cells occurs in the periphery, in the CNS, or in both locations has not yet been determined.Euclid Avenue, St. Louis, MO
.
).
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
More than 90% of multiple sclerosis (MS) patients have increased
intrathecal production of immunoglobulins, a fact that has been
known since the 1940s [1]. Because of this, for many years research on
MS focused on the humoral immune system. Nonetheless, in recent
decades (1980s and 1990s) greater emphasis was placed on the
potential pathogenic role of T lymphocytes in the pathologic process
in MS. This emphasis on T cells was based on the presence of activated
T lymphocytes in MS plaques, the strong genetic risk for MS conveyed
by certain MHC-II (HLA-DR2, critical for presentation of antigen to T
cells), and the use of an animal model for MS, experimental allergic
encephalomyelitis (EAE), which can be initiated solely by myelin-
reactive T cells [2].
Support for a critical role in MS for B lymphocytes, plasma cells, and
the antibodies (Abs) that these cells produce is found in the pathologyof
MS, which reveals the presence of plasma cells, B cells, antibody and
complement. Recently, several studies have focused on the formation of
ectopic B cell containing lymphoid tissue in MS CNS, a ﬁnding ﬁrst
reportedbyPrineas in 1979 [3]. Increased concentrationsofAbs in CSFof
MS patients have been shown in several different studies to correlate
with more aggressive types of MS, and with episodes of MS worsening
[4]. However, in addition to generation of plasma cells and Abs, B cells
have many other potential roles in the pathogenesis of MS. Theseinclude antigen uptake, processing and presentation to T cells, T cell co-
stimulation, and production of cytokines, chemokines and neurotrophic
factors. They may also play a regulatory role, through production of
regulatory cytokines (IL-10, TGFbeta) [5].
The ﬁrst part of this paper describes the evidence, both old and
new, implicating B cells, plasma cells, and Abs in the pathogenesis of
MS. We review data that suggest that autoantibodies (autoAbs)
directed against CNS myelin may contribute to MS pathogenesis. We
also point out that autoAbs may be secondary to the liberation of
antigens with CNS damage, or non-speciﬁc due to nonspeciﬁc B cell
activation. A little more than a decade ago, rituximab, a monoclonal
Ab drug speciﬁcally targeting B cells, became available to directly test
the hypothesis that B cells are critical to the pathogenesis of MS. Part
two of this paper focuses on several studies using this monoclonal Ab
inMS patients that have concluded recently. These studies are of great
interest because they have paved the way not only for new MS
treatments, but have also conﬁrmed that B cells play a key role in the
pathogenesis of the inﬂammatory, relapsing subtype of MS. However,
the means by which B cells affect MS remain unclear.2. Part 1: Evidence implicating B cells, plasma cells and antibody
in MS
2.1. The neuropathology of MS
The presence of plasma cells, myelin-speciﬁc Abs and, to a lesser
extent, B cells in both chronic MS plaques and acute MS lesions [6,7]
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globulin (Ig)G and complement deposition in MS tissues are typically
found in areas of active myelin breakdown, suggesting a role in
causation. Studies using electron microscopy and immunohistochem-
istry have provided the greatest details and will be summarized here.
Three decades ago, Esiri used immunohistochemistry to study 100
MS plaques (expanded in a later paper to 247 plaques) and to compare
these lesionswith 100 adjacent areas of normal-appearingwhitematter
(NAWM) in post-mortem CNS tissues [8]. Cells in which Abs could be
detected were far more numerous in MS plaques than in NAWM, and
also were more numerous in active than in non active plaques. Most of
the cells inwhichAbswere detectedhad themorphologic appearanceof
plasma cells. Free light chains (unassociated with heavy chains) were
commonly detected,with a higher kappa to lambda ratio found in active
plaques than in NAWM. The majority of heavy chains were of the IgG
isotype, but IgA and IgM were also detected.
Prineas and colleagues have studied the neuropathology of MS for
several decades during which time they have frequently addressed
the presence and frequency of plasma cells, B cells, immunoglobulin
and complement within MS CNS. An electron microscopic study of
autopsied CNS from sixMS and one control subject (with amyotrophic
lateral sclerosis) revealed large numbers of plasma cells in the MS
tissues, including within chronic, inactive plaques [7]. Plasma cells
were also observed in NAWM and in the leptomeninges. It was
suggested that the numerous plasma cells were the source of excess
IgG and oligoclonal bands in CSF of MS patients. The accumulation of
plasma cells at sites of chronic inﬂammation is often cited as evidence
of a local antigen-driven response [9]. However, accumulation of
plasma cells may also occur due to presence of nonspeciﬁc activators.
For example, stimulation of Toll-like receptors 2, 6, 7, 9, and 10 on
human memory B cells by their corresponding agonists can lead to
differentiation into plasma cells in an antigen non-speciﬁc manner
[10]. Other investigators have demonstrated that a particular cytokine
milieu can lead to plasma cell differentiation, in an antigen non-
speciﬁc manner [11].
2.2. Immunoglobulins in MS CNS tissues
Lucchinetti et al. performed a detailed immunohistochemical
study of active MS lesions from 83 biopsies and autopsies of MS
patients, describing four different pathologic subtypes of active MS
lesions. One subtype, Type II, involved the prominent presence of
Abs and complement, in addition to T cells and macrophages. The
Type II pattern of pathology was by far the most common (N70% of
active lesions) pattern observed [12]. Lucchinetti and colleagues
have suggested that each individual MS patient has only one of the
four subtypes of active lesion pathology, but controversy exists
regarding this, and even regarding the validity of these four subtypes
[13–15].
A recent detailed immunohistochemical study compared the
presence of immunoglobulins and activated complement components
in autopsied CNS tissues from 25 MS patients and 24 patients with
other neurological disease (OND) [13]. Although IgG was observed
within myelin in MS lesions, and in macrophages containing myelin
debris, it was also observed within astrocytes, axons (normal and
abnormal), occasional neurons, and oligodendrocytes. Moreover,
there was no difference in frequency or pattern of IgG deposition
noted between MS and OND tissues. These investigators interpreted
their ﬁndings as not supporting Ab-mediated demyelination in MS,
but rather to reﬂect a ﬁnding associated with white matter damage in
general.
2.3. Lymphoid-like tissues in MS CNS
Prineas ﬁrst reported the presence of ectopic lymphoid-like tissues
in MS CNS, using electron microscopy [3]. More recently, B-cellfollicle-like structures have been described in the meninges of some
patients with secondary progressive MS [4,16]. The presence of such
follicles indicates that a microenvironment promoting B cell expan-
sion, maturation and Ab production can exist within the CNS. The
presence of ectopic follicles in themeninges is associated with cortical
pathology and an aggressive clinical course [4]. However, formation of
ectopic follicles in chronically inﬂamed non-lymphoid organs is not
speciﬁc for MS, as these have been described in other autoimmune
diseases with a strong immune activation, such as myasthenia gravis,
autoimmune thyroiditis, and rheumatoid arthritis [17,18].
2.4. B cells and plasma cells in MS CSF
B cells are rarely observed in the CSF of healthy people, but
commonly are found in low percentage in the CSF of patients with MS
[19]. Most of the B cells in MS CSF are of the CD19+ CD27+, CD138−
phenotype, but some cells are CD19+ CD138+, indicating that they
are B cells undergoing transformation into plasma cells (plasma-
blasts) [19,20]. CSF plasma blasts are especially increased in relapsing
MS patients with clinically active disease or with gadolinium-
enhancing lesions on MRI [19,20]. Occasionally, mature plasma cells
(CD19−, CD38+, CD138+) are observed in MS CSF, but this is not
common [20]. A higher proportion of B cells relative to monocytes in
CSF correlates with more rapid disease progression [21].
2.5. Immunoglobulins in CSF
A relatively sensitive ﬁnding often used in the diagnosis of MS is
the presence in CSF of elevated concentrations of IgG, although
elevated levels of IgM, IgD, and IgA are all found in MS CSF [22–26].
Due to the blood–CNS-barrier breakdown observed in active MS
lesions and the potential contamination of CSF by serum proteins, the
IgG index was developed to take into account the level of blood–brain
barrier (BBB) integrity. The IgG index is calculated using the
concentrations of serum and CSF IgG relative to serum and CSF
albumin, because albumin, the most abundant protein in the blood, is
notmadewithin the CNS so its detection in CSF reﬂects seepage across
the BBB [27]. One small study performed on autopsied MS brains with
concurrent CSF showed a correlation between brain IgG and CSF IgG,
with the brain IgG always higher, suggesting that the CSF IgG derived
from the brain tissue itself [28]. Other more recent studies have
suggested the CSF Abs may derive from plasmablasts within the CSF.
IgG and IgM in MS CSF typically display an oligoclonal band (OCB)
pattern when these proteins are separated by electrophoresis [26].
Strong circumstantial evidence exists associating higher levels of Ig in
MS CSF with more aggressive disease. In most published studies,
elevated OCB numbers, IgG and IgM levels, and kappa light chain
concentrations in CSF all correlate with worse prognosis [29–35].
However, there are reports of OCB-positive MS having a better
prognosis than OCB-negative MS, albeit confounded by a higher
proportion of males in the OCB-negative group [36].
2.6. Autoantibodies targeting myelin proteins in cerebrospinal ﬂuid of
MS patients
Despite a multitude of studies, the OCBs in MS have not
consistently been shown to target myelin, other CNS components,
or any particular infectious agent. This was elegantly demonstrated by
Owens et al. by recombinantly generating 53 Abs from CSF B cells,
none of which reacted with the major myelin proteins [37]. Only
rarely have Abs to myelin been identiﬁed within OCBs [38]. AutoAbs
to myelin that do not correspond to the OCBs detected by
electrophoresis have been detected in MS CSF. Appropriate controls
are critical in these types of studies, as immunoglobulins can non-
speciﬁcally bind to myelin [39].
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myelin proteins have been detected in CSF. AutoAbs to myelin-
oligodendrocyte glycoprotein (MOG), a highly immunogenic but
minor component of myelin [40] and to transaldolase, an enzyme
which, in the CNS, is speciﬁc to oligodendroglia [41] have been
detected with increased prevalence in MS. Evidence exists for cross-
reactivity between epitopes of transaldolase, MBP and MOG with
epitopes of infectious agents, allowing for the possibility of molecular
mimicry in the development of these autoAbs [42,43].
2.7. Antibodies extracted from MS CNS tissue are often autoreactive with
myelin
One possibility of why Abs found in CSF of MS patients are not
often identiﬁed as autoAbs to myelin or CNS antigens is that the
relevant autoAbs are largely bound to their tissue targets, rather than
freely soluble within CSF. Several lines of evidence support this idea.
In a series of studies, Warren and Catz isolated afﬁnity puriﬁed IgG
directly fromMS plaques, and identiﬁedMBP as a target inmost cases.
The MBP (83–97) peptide appeared immunodominant since it
strongly inhibited autoAb binding to MBP in almost 100% of cases
[44]. In a subsequent study, CNS tissues from eleven of twelve MS
cases yielded IgG directed toward MBP. In 10 of the 12 cases, 10–20%
of the total IgG extracted from the CNS was anti-MBP (83–97) peptide
and in one case it represented almost 50% of the total extracted IgG
[43]. Thus, in these MS autopsies, MBP (83–97) was the dominant
autoAb target of tissue-bound IgG, This same region of MBP also
contains the dominant T cell epitope. Microbial peptides were
identiﬁed that were also bound by puriﬁed IgG extracted from MS
CNS tissue, with strong cross-binding to peptides of human
papillomavirus types 7 and 13. Puriﬁed IgG extracted from CNS of
MS autopsies also bound peptides from several other viral and
bacterial pathogens, but less well [43].
Recently, O'Connor et al. have expanded this concept by eluting
IgG from plaque regions in 14 MS cases, and from CNS tissues from 6
normal controls and 4 other inﬂammatory CNS disease controls [45].
They demonstrated speciﬁc binding with conformation-dependent
epitopes of native human MOG by IgG that had been extracted from 7
of 14 (50%)MS samples, one of the four inﬂammatory control samples
(a case of SSPE) and none of the normal samples [45].
Some of the strongest, but still circumstantial, evidence of autoAbs
being involved in myelin damage in MS derives from studies using
gold-labeled peptides of MBP and MOG [46]. These peptides bound
speciﬁcally to areas of myelin damage in sections of active MS lesions.
Control gold-labeled bovine serum albumin peptides did not bind. On
serial sections of the same CNS lesions, Abs to human IgG localized to
the same regions, providing suggestive evidence that the binding of
the peptides was due to autoreactive IgG at the sites of myelin
destruction.
It should be noted that Abs eluted from CNS tissue may represent
speciﬁc autoAb binding to antigen, but might also represent binding
to tissue components nonspeciﬁcally [39] or via Fc receptors on glial
or mononuclear cells. Moreover, the above reports are merely
associations and do not prove a role for immunoglobulins or B cells
in the pathogenesis of MS.
2.8. Autoantibodies in the blood of MS patients and controls
Serum Abs targeting myelin proteins have been reported by some
as elevated in MS patients. One report of 103 subjects with clinically
isolated demyelinating syndrome (CIS) at high risk to develop MS
suggested that the presence of serum IgM Abs detected by Western
blot to recombinant non-native MOG (prepared in E .coli) and to MBP
was predictive of more rapid development of the second attack,
marking the diagnosis of MS [47]. Subsequent studies of hundreds of
MS and CIS subjects from around the world have not been able toreproduce an association between more rapid onset of subsequent
attacks and the presence of anti-MOG or anti-MBP IgM or IgG
antibodies [48–50]. The results from subsequent studies, which have
typically utilized ELISAs rather thanWestern blots, collectively do not
support a pathogenic role for these antibodies, but instead suggest
that their presencemay be secondary to the liberation of CNS antigens
upon damage to CNS tissues.
An elegant and sensitive assay for Abs to native MOG was
developed based on binding to Jurkat cells stably transfected with a
MOG-green ﬂuorescent protein construct [51]. Serum samples from
131 pediatric MS cases, 254 adult-onset MS cases, 30 clinically
isolated syndrome (CIS) patients, and numerous control subject
groups including pediatric neurologic and non-neurological control
subjects, pediatric diabetes patients (n=28), neuromyelitis optica
cases (n=13), viral encephalitis cases (n=29) and healthy adult
controls (n=86) were tested [51]. The samples derived from
patients at many different MS centers in several countries around
the globe. Very few of the adult-onset patients had serum anti-
MOG Abs (11/254, 4.3%). Only 2 of 30 CIS serum samples contained
anti-MOG Abs which was of low binding afﬁnity. Interestingly, Abs
to MOG were detected in 28/131 pediatric-onset MS samples, with
most positive samples deriving from the patients with the
youngest ages of onset. In this study, in the small number of
cases with positive serum anti-MOG Abs in which CSF was also
tested, CSF was either negative or of lower binding than serum. Abs
to MOG were never detected in the small numbers of samples from
NMO subjects, or in the viral encephalitis cases. Thus, only a
minority of MS patients harbored Abs targeting native human
MOG. This ﬁnding suggested that autoAbs directed against native
MOG are not involved in the primary pathogenic mechanisms of
MS, or that they denote only a minor subset of primarily pediatric
MS patients. It was notable that anti-native MOG Abs were not
detected in several other destructive CNS disorders, such as viral
encephalitis.
2.9. Antibodies to non-protein CNS antigens in MS
AutoAbs against myelin lipids, especially glycolipids such as
galactocerebroside, GM4 gangliosides, and GM1 gangliosides, can be
detected in the serums and CSFs from some MS patients [52,53]. CSF
antibodies to myelin lipids have been associated with a more
aggressive MS course [33]. MS patients in the progressive stage are
reported to have a higher incidence of anti-lipid Abs than patients
with a relapsing–remitting course. However, these anti-lipid Abs can
also be found in other diseases, such as systemic lupus erythematosis
and stroke, making their signiﬁcance unclear [54].
Recently, IgM antibodies to alpha-glucose-based glycans have
been found in approximately 30% of relapsing (RRMS or SPMS)
patients, including early patients with a ﬁrst demyelinating episode
[55]. The IgM Abs are found in a much smaller proportion of PPMS
subjects, but can also be found in healthy controls. Their incidence in
other immune disorders is not reported [56]. The presence of these
serum IgM Abs may indicate a more rapid time to next relapse, but
their signiﬁcance is as yet unknown.
In summary, B cells and plasma cells can be found in autopsied and
biopsied CNS tissues from MS patients. Often they are found at the
sites of active lesions. Likewise, autoAbs to myelin proteins,
particularly MOG and MBP, can be extracted from MS tissues and
also are present in the CSF and blood of some MS patients. However,
autoAbs to myelin in blood and CSF are not speciﬁc to MS, and often
can be detected in OND subjects and other control populations. The
latter suggests that such autoAbs may develop in response to tissue
destruction and are not the primary cause of MS. Even so, autoAbs
targeting CNS components may contribute to the ongoing tissue
destruction in MS, as they have been shown to do in relevant animal
models [57].
Table 1
Expression of cell surface antigens CD19 and CD20 at various stages of development of

















CD19 0 + + + + + + 0
CD20 0 0 + + + + + 0
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3.1. B cell depleting agents
A little more than a decade ago, a therapy that speciﬁcally depletes
B cells in humans became available, providing the opportunity to test
the hypothesis that B cells are critical to the pathogenesis of MS. This
monoclonal Ab drug is rituximab (MabThera®/Rituxan®, Genentech
Inc., San Francisco, CA; IDEC Pharmaceuticals Corp, San Diego, CA;
Roche, Basle, Switzerland) (US license No. 1048). It is a genetically
engineered glycosylated immunoglobulin G1 κ chimeric mouse/
human antibody that binds to the CD20 antigen present on the
majority of circulating B cells [58]. It contains murine light- and
heavy-chain variable regions and human gamma 1 heavy-chain and
kappa light-chain constant regions. Rituximab has an approximate
molecular weight of 145 kDa. Expression of CD20 is restricted to the B
cell lineage from the pre-B cell stage until prior to the terminal
differentiation into plasma cells (Table 1).
The Fab domain of rituximab binds to CD20 on B cells and the Fc
domain recruits immune effector functions to mediate B-cell lysis in
vitro. Possible mechanisms of cell lysis in vitro include complement-
dependent cytotoxicity and antibody-dependent cell mediated cyto-
toxicity and possibly apoptosis. The relative extent to which these
individual mechanisms account for the observed depletion of B cells in
vivo is unknown but likely depends on the tissue where depletion is
occurring. Depletion in the peripheral blood is rapid and dramatic. A
recent case report in a patient with lymphoma suggests that B cell
depletion therapy is associated with the absence of B cells in the
perivascular spaces [59]. It is unclear if this effect was a direct or
indirect effect of rituximab therapy.
Rituximab was approved in the United States in November 1997
for the treatment of patients with relapsed or refractory low-grade or
follicular CD20+ B-cell non-Hodgkin's lymphoma (NHL) at a dose of
375 mg/m2 weekly for four doses. In April 2001, the FDA approved
additional claims for the treatment of low-grade NHL: retreatment
(weekly for four doses) and an additional dosing regimen (weekly for
eight doses). In February 2006, rituximab was FDA-approved for the
treatment of rheumatoid arthritis patients with inadequate response
to anti-TNFα therapy. Useful insights into administration, safety and
tolerance proﬁles have been gained through the more than 1 million
patient exposures to rituximab, as either monotherapy or in
combination with immunosuppressant drugs for up to 2 years
[60,61].
3.2. Rituximab in MS: Open-label add-on study in breakthrough RRMS
In an open-label investigator-initiated trial of rituximab as add-on
therapy to IFNB or GA in subjects with RRMS and suboptimal response
despite standard therapy, 30 subjects on ﬁrst-line disease modifying
therapies completed the regimen of four weekly infusions of 375 mg/
m2 each [62,63]. The primary endpoint of this trial was change in
number of gadolinium-enhancing lesions on three post-treatment
versus three pre-treatment brain MRIs scans. MRI results showed 88%
reduction in mean number of gadolinium-enhancing (Gd+) lesions
(pb0.0001) [74]. Although B cell numbers in CSF declined by 95% on
average between baseline and 20 weeks following the 4th dose, there
was no signiﬁcant change observed in OCB number, IgG index or CSF
IgG concentration. The number of T cells in the CSF decreased by 50%
on average [63]. A similar effect of rituximab on CSF B cells has been
reported in subjects with PPMS and RRMS [64,65]. It is unclear
whether decreased B cell numbers in CSF relates to depletion of a
trafﬁcking pool of B cells that enter the CNS from the periphery or to
entry of rituximab into the CNS. Although the number of B cells in the
CSF was greatly reduced after rituximab therapy, the proportion of B
cells that also expressed costimulatory molecules CD80 and CD86 was
increased. In the peripheral blood, unlike what was seen in the CSF,and in contrast with the dramatic B cell depletion, T cells were only
12% lower after therapy [63]. Modest reductions in serum antibodies
to MOG and MBP were seen in some subjects after therapy (week 24)
[62]. After rituximab, CSF CXCL13 and CCL19 were selectively
decreased. CXCL13 decrease correlated modestly with CSF T cell
reduction, while CCL19 did not [63]. These two chemokines are
involved in the organization of lymphoid follicles. CXCL13 is also a
chemoattractant for both B and activated T cells. Dendritic cells are
one of the sources of CXCL13 within human lymphoid tissues. In the
CNS, dendritic cells or monocytes/macrophages are believed to
produce it. CCL19 is involved in the migration of lymphocytes and
mature dendritic cells. Finally there was a negative correlation
between the changes in T cell numbers and the changes in CSF
MCP-1. The underlying biological mechanisms leading to these
chemokine changes after B cell depletion are unclear.
3.3. Phase I trial of rituximab in relapsing MS
A total of 26 subjects with RRMS were enrolled in this open-
label trial [66]. Subjects received two courses of rituximab (one
course=2,000 mg delivered as 1,000 mg each on 2 days, 2 weeks
apart) over 1 year (infusions on weeks 0 and 2, and weeks 24 and 26).
Enrolled subjects had a mean age of 40.4±8.7 years. At baseline,
mean EDSS score was 2.3.
Subjects had a mean of 1.27 relapses during the previous year.
Over the 72 weeks, 21 (80.8%) subjects remained relapse-free; 4
subjects (15.4%) reported 1 relapse and 1 subject (3.8%) reported 2
relapses. The unadjusted annualized relapse rate was 0.25 and 0.18,
from baseline to week 24, and from baseline to week 72,
respectively.
The mean number of Gd+ lesions decreased from 1.31 (baseline)
to 0.73 (week 4) after the ﬁrst course of rituximab. After the second
course, the mean number of Gd+ lesions decreased to 0.05 (week 48)
and 0 (week 72). The mean number of new T2-bright lesions
decreased from 0.92 at week 4 to 0 at week 72.
3.4. Phase II placebo-controlled trial of rituximab in RRMS
A multicenter trial of rituximab in RRMS (funded by Genentech,
Inc. and Biogen Idec, Inc.) enrolled 104 subjects, 69 were randomized
to rituximab and 35 to placebo [67]. Of 104 subjects, 96 (92.3%)
completed 24 weeks, and 79 subjects (76%) completed 48 weeks,
including 84.1% in the rituximab group and 60% in the placebo group.
Twelve of the 25 subjects who discontinued the study treatment
period early completed the safety follow-up, including 10.1% of
subjects in the rituximab group and 14.3% of subjects in the placebo
group [67].
3.4.1. Primary endpoint (intent-to-treat analysis)
Rituximab-treated subjects demonstrated a dramatic reduction in
total Gd+lesion counts at weeks 12, 16, 20, and 24 compared with
placebo-treated subjects (pb0.001). Those receiving rituximab had a
mean of 0.5 Gd+ lesions, compared with 5.5 in those receiving
placebo, a relative reduction of 91%. Beginning at week 12, compared
with placebo, rituximab signiﬁcantly reduced Gd+ lesions at each
subsequent study visit (p=0.003 to b0.001).
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The proportion of subjects with relapses was reduced in the
rituximab group compared with placebo at week 24 (14.5% versus
34.3%, p=0.02) and week 48 (20.3% versus 40.0%, p=0.04). At week
24, placebo recipients were at double (2.31) the risk of relapse
compared with rituximab-treated subjects; at week 48, the relative
risk of relapse was 1.90.
Beginning at week 12, rituximab also signiﬁcantly reduced the
number of newGd+ lesions at each studyweek (p=0.002 to b0.001).
3.4.3. Immunologic studies
B-cell depletion, both ex vivo and in vivo resulted in signiﬁcantly
diminished pro-inﬂammatory Th1 and Th17 responses of both CD4
and CD8 T cells. Soluble products from activated B cells of untreated
MS subjects reconstituted the diminished T-cell responses observed
following in vivo B-cell depletion in the same subjects, and this effect
appeared to be largely mediated by B-cell lymphotoxin and tumor
necrosis factor-alpha [68]. These ﬁndings of decreased peripheral T
cell activation and proliferation in the absence of B cells would be
expected to result in lesser T cell trafﬁcking into the CSF compartment.
3.5. Phase II/III trial in primary progressive MS
A phase II/III trial in PPMS (OLYMPUS, funded by Genentech, Inc.
and Biogen-Idec, Inc.) tested the effect of rituximab versus placebo in
450 subjects for a total of 2 years of therapy [69]. Using 2:1
randomization, 439 PPMS subjects received either two 1,000 mg
rituximab infusions or two placebo infusions (separated by 2 weeks)
intravenously every 24 weeks, (four treatment courses) through
96 weeks. Mean baseline EDSS was 4.8. Half of the subjects were
males, and median age at baseline was 51 years.
Primary endpoint: time to conﬁrmed disease progression (CDP),
deﬁned by a pre-speciﬁed increase in EDSS sustained for 12 weeks
(increased by at least 1.0 point from baseline if EDSS between 2.0 and
5.5 inclusive; increased by at least 0.5 point if EDSSN5.5). The
difference in time to CDP between treatment arms was not
statistically signiﬁcant (p=0.14, stratiﬁed log-rank test). Kaplan–
Meier estimates for the proportion of subjects with CDP at 96 weeks
were 38.5% for placebo and 30.2% for rituximab (e.g. a 24% reduction
in the risk of progression in rituximab recipients).
Secondary imaging endpoints: Rituximab recipients had less T2
lesion volume increase than placebo recipients (pb0.001) while brain
volume change was similar in both groups (p=0.62). Median
increase in the T2 lesion volume was 302.95 mm3 for rituximab
treated subjects and 809.50 mm3 for placebo treated subjects.
Exploratory endpoints: compared with placebo, rituximab treated
subjects had less worsening in the timed 25-ft walk at weeks 48, 96
and 122. Other MSFC items showed no difference between groups.
Pre-planned sub-group analysis showed that subjects under
51 years of age, who had Gd+ lesions at baseline or who had
progression the year before study participation were more likely to
beneﬁt from treatment.
3.6. Clinical safety and tolerability
3.6.1. Side effects of rituximab
The most common side effects of rituximab are infusion reactions
including fever, chills, rigors, hypotension and general ﬂu-like
symptoms. These generally occur during the ﬁrst infusion and the
majority is classiﬁed as mild or moderate. Rarely, severe and fatal
infusion-related reactions have occurred in lymphoma patients. Risk
factors for serious infusion reactions in lymphoma patients include
high tumor burden, high circulating lymphocyte counts, and concur-
rent cardiovascular or pulmonary disease. Rituximab does not appear
to signiﬁcantly increase the rate of serious infections in most studies
to date [60,61,70]. However, several cases of progressive multifocalleukoencephalopathy (PML) have been reported in patients receiving
rituximab and concurrent or prior therapy with other immunosup-
pressive therapies for lymphoma, rheumatoid arthritis or systemic
lupus erythematosis. Thus far, no PML cases have been reported in
patients with MS, or in patients with other conditions receiving
rituximab as a monotherapy who had not been exposed to prior
immunosuppression or did not have another potential reason to
develop PML.
3.6.2. Rituximab side effects in MS
All three trials in RR and PPMS of rituximab monotherapy have
conﬁrmed a side effect proﬁle similar to that previously reported in
rheumatoid arthritis and other autoimmune disorders. The most
common (≥10%) drug-related adverse events (AEs) in the rituximab
group were infusion-associated. Most infusion-related AEs occurring
with the ﬁrst infusion in MS subjects were mild or moderate (N90%),
while 7% were grade 3 and none were grade 4. Rates of infusion-
related AEs were comparable to placebo upon successive infusions. In
the phase II trial in RRMS, grade 4 events were reported in three
rituximab subjects: ischemic coronary artery disorder (1), malignant
thyroid neoplasm (1), and acute and progressive MS symptoms (1).
Serious AEs (SAEs) were reported in 14.3% of subjects in the placebo
group and 13% of subjects in the rituximab group. A total of 5.7%
placebo subjects and 4.3% of rituximab subjects withdrew from the
study due to AEs. One death (homicide) occurred in the rituximab
group.
In the phase II RRMS trial, the incidence of infection was similar in
the placebo (71.4%) and rituximab (69.6%) groups. The most common
(≥10%) infections in rituximab-treated subjects were nasopharyngi-
tis, upper respiratory tract infections, urinary tract infections, and
sinusitis. Urinary tract infections (14.5% rituximab vs. 8.6% placebo)
and sinusitis (13.0% vs. 8.6%) were more common in rituximab-
treated subjects. No opportunistic infections were reported. Infectious
SAEs were reported by 5.7% of placebo subjects and 2.9% of rituximab
subjects. Of the two serious infection-related AEs in the rituximab
group (gastroenteritis, bronchitis), both resolved without sequelae;
the last recorded values for immunoglobulin levels prior to these
infections were above the lower limit of normal in both subjects.
In the PPMS phase II/III trial, infection-related SAEs were higher in
the rituximab group than the placebo group (4.5% vs. b1.0%). Three
subjects died, one from each groupwith pneumonia, and one from the
placebo group due to cardiopulmonary failure [69]. Although likely
too small to be conclusive, there was no evidence for increased
incidence of infection or other adverse events in subjects with Ig
levels below the lower limit of normal (LLN).
3.7. Dosing and pharmacokinetics
3.7.1. Dosing
Rituximab was initially approved in lymphoma at a dose of
375 mg/m2 weekly for four doses. Subsequently, the regimen was
changed to a ﬁxed dose of 2,000 mg (two infusions of 1,000 mg,
2 weeks apart) based on safety, pharmacokinetic, pharmacodynamic
and efﬁcacy data in lymphoma and rheumatoid arthritis (Edwards,
2004).
3.7.2. Pharmacodynamics and immunogenicity in MS trials
One uncontrolled phase I and one randomized phase II trial in
RRMS, and one randomized phase III study in PPMS have provided
detailed information on the pharmacodynamics and immunogenicity
of rituximab in MS subjects [66,67]. In these trials, rituximab induced
near-complete depletion of CD20-positive peripheral B-cells (mea-
sured by CD19 expression) (N95% reduction from baseline) byweek 2.
In the phase II trial (one course of rituximab at weeks 0 and 2 vs.
placebo), depletion was sustained through 24 weeks; by week 48,
CD19-positive cells had returned to 30.7% of baseline values. CD3 T
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Similarly, in the phase I study (two courses of 1,000 mg rituximab at
weeks 0 and 2, and at weeks 24 and 26) depletion was complete up to
week 48, with reconstitution to mean 34.5% of baseline by week 72.
The majority of reconstituting cells were CD19-positive/CD27-
negative naïve B cells (mean 51% of baseline) rather than CD19-
positive/CD27-positive memory B cells (mean 14% of baseline)
suggesting that naïve B cells appear to recover faster than memory
B cells. Circulating B cells are replenished from bone marrow pro-B
cells within 4 to 12 months after depletion, sometimes longer.
In the phase II monotherapy study, median IgM, IgG, and IgA levels
remained above the lower limit of normal (LLN) in both treatment
groups throughout the trial. At any time through week 48, IgG levels
were below LLN in 7.9% of rituximab-treated subjects and 3.0% of
placebo-treated subjects, and IgM levels were below the LLN in 22.4%
of rituximab subjects and 8.6% of placebo subjects. No subject had IgA
levels below the LLN during the study. In the phase I study, serum IgG
titers for tetanus generally remained unchanged over 72 weeks and
no subject who was seropositive for mumps or rubella at baseline
became seronegative during the study. In the phase III OLYMPUS
study, IgG and IgA levels were below LLN range in b5% of subjects in
either treatment arm. IgM were below LLN at some time during the
study in 31.7% of rituximab recipients and 5.9% of placebo recipients
[69].
In the phase II trial at week 48, of 58 subjects who completed the
treatment period, 14 (24.1%) tested positive for human anti chimeric
antibodies (HACA) to rituximab; no placebo subject tested positive at
any time. There was no apparent association between HACA positivity
and the type or severity of adverse events or efﬁcacy response at
weeks 24, 36, or 48 but this trial did not evaluate the efﬁcacy of
rituximab re-administration. In the Phase II add-on trial, 13% of
subjects developed HACA by 24 weeks after therapy [74]. Surprisingly,
in the PPMS trial [69], 7% of rituximab recipients and 6.3% of placebo
recipients were positive for HACA. The reason for the presence of
HACA in placebo recipients in this study is less clear.
3.8. Off-label B cell depletion in MS patients
Rituximab is not approved for use in MS patients. Nonetheless, it is
currently used off-label by some physicians for MS patients failing
approved therapies for MS. The optimal frequency of rituximab
administration and how long subjects should be retreated is unclear.
Moreover, the risks of long-term B cell depletion in MS patients are
unknown. It remains to be seen whether the rate of infections
increases with long term B cell depletion. Furthermore, no data are
available regarding the efﬁcacy of vaccinations performed in patients
undergoing chronic B cell depletion.
The next generation of anti-CD20 monoclonal Ab is under clinical
evaluation. Ocrelizumab is a humanized Ab which has a lower rate of
potentially neutralizing human antihumanized Abs development and
infusion reactions than rituximab. Ocrelizumab is being tested in MS.
Other humanized antiCD20 molecules are being developed and
include both monoclonal Abs and small molecules. Other therapeutic
strategies that aim to target B cells later in B cell development
(atacicept) have failed in MS trials as one study was interrupted
prematurely due to unexpected increase in disease activity. Thera-
peutic strategies that aim tomodify B cell response (BAFF-receptor Ig)
have not been tested in MS.
3.9. What have we learned from B cell depletion trials in humans?
The four trials of rituximab that have been performed in RRMS and
PPMS have all shown a beneﬁt in terms of brain MRI Gd+ lesion
reduction. From the studies in RRMS, Gd+ lesion reduction appears to
be very prompt in onset (i.e. beginning within a few weeks after
treatment administration). The phase II placebo-controlled trial inRRMS also suggested a substantial clinical reduction in relapses
during the 12 months following treatment, when subjects were
depleted of circulating B cells. While the effect of rituximab on the
inﬂammatory component of the disease is obvious, the effect on
insidious disability progression such as occurs in PPMS is unclear.
B cell depletion in MS subjects did not signiﬁcantly alter CSF IgG
levels; IgG Index, IgG concentration, IgG synthesis rate and oligoclonal
bands did not change signiﬁcantly after treatment [62,63]. However, B
cell depletion induced a delayed and marginal reduction of IgG and
IgM blood levels. This effect likely requires several rounds of
treatment over several months, as the Ab-secreting plasmocytes
become CD20 negative upon differentiation from B cells. Thus, mature
plasma cells are not directly impacted by rituximab. However, as
rituximab depletes the pool of B cells differentiating into plasma cells
secreting Ig, chronic B cell depletion appears to initially affect IgM and
subsequently IgG levels. Whether these changes participate in disease
modiﬁcation is unknown. With respect to the notion of using
rituximab based on its potential to impact autoAb production, it is
important to keep in mind reports that some CNS autoAbs may
actually have positive effects on remyelination [71,72].
While B cells return several months after B cell depletion, there
seems to be a differential impact on various B cell subtypes. Naïve B
cells (CD27−) return much earlier than memory B cells (CD27+)
[73]. This observation has raised the question whether rituximab
might be “resetting” the B cell immunologic clock.
4. Conclusion and future perspectives
The dramatic reduction of Gd+ lesions on brain MRI in RRMS that
has now been observed in three separate trials of B cell depletion
using rituximab has conﬁrmed a pathogenic role of B cells in the
development or maintenance of inﬂammatory MS lesions. The
mechanisms by which the effect occurs remain unknown. The rapid
impact of rituximab in RRMS argues for a main effect related to
antibody-independent B cell functions. One of the striking ﬁndings in
the open label add-on trial was the dramatic reduction in B cells in the
CSF, with a lesser reduction in CSF T cells. In the context of the
marginal reduction in peripheral T cells [63] and the diminished pro-
inﬂammatory response of both CD4 and CD8 T cells [68], the 50%
reduction of CSF T cells suggests a decreased ability of peripheral T
cells to enter the CSF compartment. Thus, B cells may be directly or
indirectly critical to the ability of T cells to trafﬁc into the CNS. The
effect of B cell depletion in terms of antibody independent immune
response is likely complex, and as suggested by Piccio et al. and Bar-Or
et al., could be mediated via an effect on decreased T cell migration
and proliferation, and decreased release of pro-inﬂammatory cytokine
by B cells and possible indirect consequences on dendritic cells. Future
studies to analyze the effects of B cell depletion on antigen uptake,
processing and presentation to T cells in MS patients promise to
provide further understanding of the role of B cells in MS.Acknowledgements
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